Pharmaceutical secondary standards for application in quality control provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards
1-Methylnicotinamide (MNA) is a primary metabolite of nicotinamide produced mainly by nicotinamide N-methyltransferase (NNMT). 1-Methylnicotinamide (MNA) has been shown to have antithrombotic and anti-inflammatory effects. A recent study indicated that MNA may exert antithrombotic and anti-inflammatory effects through direct action on the endothelium, with a vasorelaxing effect by enhancement of NO bioavailability and reduction of eNOS-dependent oxidative stress. Enhanced NNMT activity is a feature of many types of cancer. How much direct involvement MNA has in the tumorigenesis associated with overexpression of NNMT is under investigation. MNA by itself increased mitochondrial Complex I activity and increased cancer cell viability in SH-SY5Y neuroblastoma cells that do not produce NNMT.
Komentarz do analizy
These secondary standards offer multi-traceability to the USP, EP and BP primary standards, where they are available.
This Certified Reference Material (CRM) is produced and certified in accordance with ISO 17034 and ISO/IEC 17025. All information regarding the use of this CRM can be found on the certificate of analysis.
To see an example of a Certificate of Analysis for this material enter LRAB9787 in the Documents slot below. This is an example certificate only and may not be the lot that you receive.